Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Biomarker Identification for Idiopathic Pulmonary Fibrosis (IPF)

FY 2024-25

Summary
Idiopathic pulmonary fibrosis (IPF) is a serious health problem of the lungs that gets worse over time. If we could recognize the disease early on and give treatment before too much lung damage happens, then breathing will be less difficult, and patients can survive longer. The goal of this project is to identify biomarkers which are molecules in the blood that we can measure and use to determine if a person has the disease in its early stages. To accomplish this, we will study blood samples of patients living with and without IPF. First, we will measure the amount and determine the content of extracellular vesicles in the blood. Extracellular vesicles are small spheres released by cells into the blood that carry molecules which can influence the function of other cells. Investigating the contents of these extracellular vesicles will allow us to detect biomarkers for this disease and it will help us understand their role in IPF. In addition, we will study the circulating cell-free DNA which are short pieces of DNA that are released by cells into the blood. We will determine changes in the circulating cell-free DNA in the blood of patients. These changes can also serve as a biomarker for IPF. It is very difficult to recognize IPF in people before the disease destroys the lungs. Our project will be the first to establish many potential new biomarkers that can be used to determine if patients are in the early stages of the disease. This will lead to increasing patients' lifespan if treated early. As no treatment exists to cure IPF, this project will also help us understand how the disease develops which will be useful for developing new drugs that protect the lungs from more damage and restore patient health.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530251
Name
Wahab Fariya
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Biomarker Identification for Idiopathic Pulmonary Fibrosis (IPF)
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Blood; Cell-Free Dna; Extracellular Vesicles; Fragment Size; Idiopathic Pulmonary Fibrosis; Lung; Methylation; Plasma; Protein; Respiration
Abstract
Idiopathic pulmonary fibrosis (IPF) is a serious health problem of the lungs that gets worse over time. If we could recognize the disease early on and give treatment before too much lung damage happens, then breathing will be less difficult, and patients can survive longer. The goal of this project is to identify biomarkers which are molecules in the blood that we can measure and use to determine if a person has the disease in its early stages. To accomplish this, we will study blood samples of patients living with and without IPF. First, we will measure the amount and determine the content of extracellular vesicles in the blood. Extracellular vesicles are small spheres released by cells into the blood that carry molecules which can influence the function of other cells. Investigating the contents of these extracellular vesicles will allow us to detect biomarkers for this disease and it will help us understand their role in IPF. In addition, we will study the circulating cell-free DNA which are short pieces of DNA that are released by cells into the blood. We will determine changes in the circulating cell-free DNA in the blood of patients. These changes can also serve as a biomarker for IPF. It is very difficult to recognize IPF in people before the disease destroys the lungs. Our project will be the first to establish many potential new biomarkers that can be used to determine if patients are in the early stages of the disease. This will lead to increasing patients' lifespan if treated early. As no treatment exists to cure IPF, this project will also help us understand how the disease develops which will be useful for developing new drugs that protect the lungs from more damage and restore patient health.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wahab, Fariya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~